You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,419,983


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,419,983
Title:Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001## wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.2a, R.sub.2b, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s): Guo; Zhiqiang (San Diego, CA), Chen; Yongsheng (San Diego, CA), Wu; Dongpei (San Diego, CA), Chen; Chen (San Diego, CA), Wade; Warren (San Diego, CA), Dwight; Wesley J. (San Diego, CA), Huang; Charles Q. (San Diego, CA), Tucci; Fabio C. (San Diego, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:11/627,204
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,419,983
Patent Claims: 1. A compound having the following structure (I): ##STR00047## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R.sub.1a is halogen; R.sub.1b is alkoxy; R.sub.1c is hydrogen; R.sub.2a is halogen; R.sub.2b is trifluoromethyl; R.sub.3 is methyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is --COOH; and X is C.sub.1-6alkanediyl.

2. The compound according to claim 1, wherein R.sub.1a is at the 2-position of the phenyl ring and R.sub.1b is at the 3-position of the phenyl ring.

3. The compound according to claim 2, wherein R.sub.1a is fluoro or chloro and R.sub.1b is methoxy.

4. The compound according to claim 1, wherein R.sub.2a is at the 2-position of the phenyl ring and R.sub.2b is at the 6-position of the phenyl ring.

5. The compound according to claim 4, wherein R.sub.2a is fluoro.

6. The compound according to claim 1, wherein R.sub.1a is fluoro or chloro.

7. The compound according to claim 6, wherein R.sub.1b is methoxy.

8. The compound according to claim 7, wherein R.sub.2a is fluoro.

9. The compound according to claim 8, wherein X is --CH.sub.2CH.sub.2CH.sub.2--.

10. The compound according to claim 9, wherein R.sub.1a is fluoro.

11. The compound according to claim 9, wherein R.sub.1a is chloro.

12. The compound according to claim 1, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3- methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-- 2,4(1H,3H)-dione,3-[2(R)-{hydroxylcarbonylpropyl-amino}-2-phenylethyl]-5-(- 2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylp- yrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 13, wherein the compound is the sodium salt or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

15. The compound according to claim 14, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

16. The compound according to claim 14, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

17. The compound according to claim 12, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 17, wherein the compound is the sodium salt or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

19. The compound according to claim 18, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

20. The compound according to claim 18, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound having the following structure (I): ##STR00048## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R.sub.1a is halogen; R.sub.1b is alkoxy; R.sub.1c is hydrogen; R.sub.2a is halogen; R.sub.2b is trifluoromethyl; R.sub.3 is methyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is --COOH; and X is C.sub.1-6alkanediyl.

22. The pharmaceutical composition according to claim 21, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chlor- o-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidi- ne-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

23. The pharmaceutical composition according to claim 22, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2phenylethyl]-5-(2-fluoro-3-methoxy- phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3- H)-dione or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition according to claim 23, wherein the compound is the sodium or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

25. The pharmaceutical composition according to claim 24, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino }-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromet- hyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione.

26. The pharmaceutical composition according to claim 24, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

27. The pharmaceutical composition according to claim 22, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione or a pharmaceutically acceptable salt thereof.

28. The pharmaceutical composition according to claim 27, wherein the compound is the sodium salt or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

29. The pharmaceutical composition according to claim 28, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

30. The pharmaceutical composition according to claim 28, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

31. A method for treating a condition selected from the group of prostate cancer, benign prostatic hypertrophy, breast cancer or endometriosis in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound having the following structure (I): ##STR00049## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: R.sub.1a is halogen; R.sub.1b is alkoxy; R.sub.1c is hydrogen; R.sub.2a is halogen; R.sub.2b is trifluoromethyl; R.sub.3 is methyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is --COOH; and X is C.sub.1-6 alkanediyl.

32. The method according to claim 31, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione,3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro- -3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidin- e-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

33. The method according to claim 32, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione or a pharmaceutically acceptable salt thereof.

34. The method according to claim 33, wherein the compound is the sodium or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

35. The method according to claim 34, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-- 3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine- -2,4(1H,3H)-dione.

36. The method according to claim 34, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-- 3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine- -2,4(1H,3H)-dione.

37. The method according to claim 32, wherein the compound is 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione or a pharmaceutically acceptable salt thereof.

38. The method according to claim 37, wherein the compound is the sodium salt or calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-3-methox- yphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,- 3H)-dione.

39. The method according to claim 38, wherein the compound is the sodium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-- 3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine- -2,4(1H,3H)-dione.

40. The method according to claim 38, wherein the compound is the calcium salt of 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-chloro-- 3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine- -2,4(1H,3H)-dione.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.